The Research Roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Multiple myeloma is the second most common hematological malignancy and was expected to cause over 12,000 deaths in the United States in 2018. Translational research with introduction of proteasome inhibitors and immunomodulatory drugs and use of high-dose therapy with autologous stem cell transplant (ASCT) has consistently improved the outcomes in patients with multiple myeloma over the past two decades. Multiple myeloma is clinically and biologically heterogeneous and outcomes are influenced by a variety of factors including patient characteristics, tumor load, and disease biology, including the genomic abnormalities in malignant plasma cells (PCs). Recurrent cytogenetic abnormalities detected by interphase fluorescent in situ hybridization (FISH) on malignant PCs give key prognostic information. Deletion of short arm of chromosome 17 (17p13.1) is one of the adverse cytogenetic markers at diagnosis.